Novo Nordisk is the drug company that makes Wegovy and Ozempic.

诺和诺德是生产Wegovy和Ozempic的制药公司。

Another drug made by Novo Nordisk, Wegovy, is a weekly injection.

诺和诺德公司生产的另一种药物Wegovy是每周注射一次。

The drug, made by Novo Nordisk, is set to come off patent soon.

该药物由诺和诺德公司生产，专利即将到期。

Our contributor Sara Reardon also reached out to Novo Nordisk and Eli Lilly.

我们的投稿人 Sara Reardon 还联系了诺和诺德和礼来公司。

Novo Nordisk is their new port of call.

诺和诺德是他们的新停靠港。

Novo Nordisk said in a statement it was not involved in the request to consider liraglutide for the WHO list.

诺和诺德公司在一份声明中表示，它没有提出考虑将利拉鲁肽列入世卫组织清单的请求。

Eli Lilly, Novo Nordisk and Sanofi should answer our calls for transparency.

礼来、诺和诺德和赛诺菲应该响应我们对透明度的呼吁。

Sanofi, Eli Lilly and Novo Nordisk, control nearly 96 percent of the world's insulin supply.

赛诺菲、礼来和诺和诺德控制着全球近 96% 的胰岛素供应。

Findings of a late stage trial for Novo Nordisk's weight loss drug came out yesterday.

诺和诺德减肥药的后期试验结果昨天公布。

Instead of buying insulin from big pharmaceutical companies such as Eli Lilly, Novo Nordisk, they want to make their own insulin.

他们不想从礼来、诺和诺德等大型制药公司购买胰岛素，而是想自己制造胰岛素。

Novo Nordisk, a Danish pharmaceutical giant, is one of the firms trying to make medicines using miRNAs.

丹麦制药巨头诺和诺德公司是尝试利用 miRNA 生产药物的公司之一。

The combined market capitalisation of Novo Nordisk and Eli Lilly easily eclipses that of AstraZeneca, Moderna and Pfizer put together.

诺和诺德和礼来的总市值很容易超过阿斯利康、Moderna 和辉瑞的总和。

So this new generation of weight loss drugs are made by the Danish company Novo Nordisk and US drugmaker Eli Lilly.

所以这种新一代减肥药是由丹麦诺和诺德公司和美国制药商礼来公司生产的。

It works like this: Ozempic and Wegovy, which were both developed by the company Novo Nordisk, are brands of one specific drug called semaglutide.

它的工作原理是这样的：Ozenpic和Wegovy都是由诺和诺德公司开发的，它们是一种名为Semagrutide的特效药的品牌。

Instead, just by slightly tweaking formulas or packaging, Eli Lilly, Novo Nordisk and Sanofi can extend patents, increase prices and prevent affordable generics.

相反，只需稍微调整配方或包装，礼来、诺和诺德和赛诺菲就可以延长专利、提高价格并阻止可负担得起的仿制药。

The authors, Carlos Monteiro of the University of Sao Paulo and Ana Ostrom of Novo Nordisk Foundation, will discuss the issue in a live virtual debate August 14th during Nutrition 2024 Live Online.

作者圣保罗大学的卡洛斯·蒙泰罗和诺和诺德基金会的安娜·奥斯特罗姆将于 8 月 14 日在 2024 年营养大会在线直播期间进行现场在线辩论， 讨论这一问题。

The Novo Nordisk foundation, in Denmark, is testing a hybrid system that rejects projects assessed as being of poor quality, gives money to good ones, and randomly hands cash to some of those judged middling.

丹麦的诺和诺德基金会正在测试一种混合系统，该系统拒绝被评估为质量差的项目，向优质项目提供资金， 并随机向一些被评定为中等的项目提供现金。

" I needed some help." So his doctor, a family friend, suggested he use an injectable drug from Novo Nordisk, a Danish drugmaker, that is approved for type-2 diabetes but, as a fringe benefit, helps with weight loss, too.

“我需要一些帮助。”因此，他的医生，一位家庭朋友，建议他使用丹麦制药商诺和诺德 (Novo Nordisk) 的注射药物，该药物被批准用于治疗 2 型糖尿病，但作为附带福利，它也有助于减肥。